Abstract
Diabetes mellitus is a chronic condition prevalent worldwide. It is estimated that more than 246 million individuals have diabetes, with this number expected to increase to 366 million by the year 2030. The chronic hyperglycemia of diabetes is associated with long term damage to various organs, including the eyes, kidneys, nervous system, heart, and vasculature. India has a long history regarding the epidemiology of diabetes. In an effort to optimize glycemic control and also to reduce the burden of diabetic complications, several classes of oral hypoglycemic agents have been developed. Linagliptin has now been on the market and has been established as the first-line agent of choice for the management of type 2 diabetes. In this way, linagliptin is anticipated to reduce insulin resistance, contribute to weight loss, and play a significant role in the improvement of cardiovascular outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
